Key New Lymphoma Research Findings

According to a new study conducted by the scientists at BC Cancer Agency (BCCA) and several at the Simon Fraser University, two-thirds of newly identified mutated genes are in some way linked to lymphoma.

Published in the journal Nature, the report indicates that two newly discovered lymphoma-related genes enable cancer cells to grow rapidly despite the body’s regulatory systems. In order to come to their conclusions, 50 BCCA scientists discovered 109 genes with recurring mutations while they were in the process of sequencing the whole genomes of over 100 diffuse large B-cell lymphoma tumors. They then identified 26 of the repeatedly mutated genes as contributors to the disease.

The study notes that the mutations inactivate MLL2 -- which usually works as a tumor stopping gene -- and thereby allows for the cancer cells to develop more quickly.

“The mutated genes discovered should enable the design of new tests to recognize subtypes of lymphoma,” explains Angela Brooks-Wilson, one of the BCCA scientists on this study. Also an associate professor of biomedical physiology and kinesiology at SFU, Brooks-Wilson adds: “The findings may help us predict how individual lymphoma tumours will react to different treatments.”

“This wealth of new genetic clues will help us create new drugs and identify existing ones that can inhibit these mutant genes,” says Steven Jones, a professor of molecular biology and biochemistry (MBB) at SFU. “The pattern of mutations discovered may become ideal targets for existing therapies.”

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap